Drug Profile
Teplizumab - Provention Bio
Alternative Names: hOKT3-gamma-1-ala-ala; hOKT3-γ1-ala-ala; MGA-031; PRV 031; PVR031; Teplizumab-mzwv; TZIELDLatest Information Update: 10 Apr 2024
Price :
$50
*
At a glance
- Originator Tolerance Therapeutics
- Developer MacroGenics; Provention Bio
- Class Antihyperglycaemics; Monoclonal antibodies
- Mechanism of Action CD3 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Type 1 diabetes mellitus
- Discontinued Multiple sclerosis; Psoriasis; Psoriatic arthritis
Most Recent Events
- 22 Jan 2024 Provention Bio completes a phase-II clinical trials in Type 1 diabetes mellitus (In adolescents, In adults, In children, In the elderly) in USA (IV) (NCT04270942)
- 01 Nov 2023 Tolerance Therapeutics has been acquired and merged into Ligand Pharmaceuticals
- 18 Oct 2023 Efficacy and adverse events data from a phase III PROTECT trial in Type 1 diabetes mellitus released by Sanofi